| Literature DB >> 32284049 |
Tuva Moseng1, Hanne Dagfinrud2, Leti van Bodegom-Vos3, Krysia Dziedzic4, Kåre Birger Hagen2, Bård Natvig5, Jan Harald Røtterud6, Thea Vliet Vlieland7, Nina Østerås2.
Abstract
BACKGROUND: To address the well-documented gap between hip and knee osteoarthritis (OA) treatment recommendations and current clinical practice, a structured model for integrated OA care was developed and evaluated in a stepped-wedge cluster-randomised controlled trial. The current study used secondary outcomes to evaluate clinically important response to treatment through the Outcome Measures in Rheumatology Clinical Trials clinical responder criteria (OMERACT-OARSI responder criteria) after 3 and 6 months between patients receiving the structured OA care model vs. usual care. Secondly, the study aimed to investigate if the proportion of responders in the intervention group was influenced by adherence to the exercise program inherent in the model.Entities:
Keywords: Adherence; Exercise; Function; Hip; Knee; Management; Osteoarthritis; Pain; RCT; Responder
Mesh:
Year: 2020 PMID: 32284049 PMCID: PMC7155273 DOI: 10.1186/s12891-020-03235-z
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1The stepped-wedge cluster randomized design as applied for the SAMBA study
Baseline characteristics of patients with osteoarthritis participating in the SAMBA study
| All participants | Intervention group | Control group | |
|---|---|---|---|
| ( | ( | ( | |
| Age, mean (SD) | 63 (10) | 63 (10) | 65 (10) |
| Sex, female, n (%) | 280 (71) | 211 (74) | 68 (62) |
| BMI, mean (SD) | 29 (6) | 29 (6) | 28 (5) |
| Education | |||
| ≥ 1 year university, n (%) | 136 (35) | 101 (36) | 35 (32) |
| Main affected joint, n (%) | |||
| Knee | 228 (58) | 174 (61) | 54 (49) |
| Hip | 146 (37) | 100 (35) | 46 (42) |
| Other* | 18 (6) | 9 (3) | 9 (8) |
| Multi-site OA, n (%)** | 339 (86) | 244 (86) | 95 (87) |
*OA joint other than hip and knee (e.g. hand, ankle) is the main affected joint ** ≥ 2 affected joints
Fig. 2Flowchart of participants’ progress through the phases of the trial. *Refers to the questions regarding pain, function and disease activity
Differences in patient-reported outcomes and OMERACT-OARSI responders between the intervention and control group at 3 and 6 months follow-up
| Intervention group | Control group | Control vs. intervention 3 mos. (95% CI) | Control vs. intervention 6 mos. (95% CI) | Control vs. Intervention group 3 + 6 mos. (95% CI) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL | 3 mos. | 6 mos. | 3 + 6 mos. | BL n = 109 | 3 mos. | 6 mos. | 3 + 6 mos. | |||||||
| Pain last week (NRS 0–10), mean (SD) | 5.4 (2.0) | 4.4 (2.0) | 4.2 (2.1) | 5.1 (1.8) | 4.7 (2.2) | 4.7 (2.1) | b: −0.65 (−1.26, −0.04) | 0.04 | b: − 0.98 (− 1.59, − 0.37) | 0.002 | ||||
| Function last week (NRS 0–10), mean (SD) | 5.2 (2.0) | 4.4 (1.9) | 4.1 (2.1) | 4.9 (1.9) | 4.6 (2.3) | 4.7 (2.1) | b: −0.67 (−1.28, − 0.06) | 0.03 | b: − 1.17 (− 1.78, − 0.56) | < 0.001 | ||||
| Disease activity last week (NRS 0–10), mean (SD) | 5.3 (2.0) | 4.3 (2.0) | 4.2 (2.1) | 4.8 (2.0) | 4.7 (2.3) | 4.7 (2.2) | b: −0.93 (−1.55, − 0.31) | 0.003 | b: − 1.02 (− 1.64, − 0.39) | 0.001 | ||||
| OMERACT-OARSI responders, n (%) | 92 (33) | 99 (35) | 132 (47) | 24 (23) | 24 (23) | 36 (35) | OR: 1.37 (0.26, 7.24) | 0.7 | OR: 2.81 (0.32, 24.67) | 0.3 | OR: 1.38 (0.41, 4.67) | 0.6 | ||
| Stiffness last week (NRS 0–10), mean (SD) | 5.3 (2.3) | 4.5 (2.1) | 4.3 (2.1) | 4.9 (2.2) | 4.6 (2.1) | 4.9 (2.1) | b: −0.63 (−1.28, 0.01) | 0.05 | b: − 1.10 (− 1.74, − 0.45) | 0.001 | ||||
| H/KOOS QoL subscale mean (SD) | 44.9 (16.3) | 47.8 (14.9) | 49.7 (15.8) | 49.9 (17.2) | 45.3 (18.2) | 47.2 (17.5) | b: 5.43 (0.59, 10.27) | 0.03 | b: 5.11 (0.28, 9.95) | 0.04 | ||||
| Daily hours in sitting position, mean (SD) | 6.5 (2.8) | 6.1 (2.8) | 5.9 (2.6) | 6.8 (3.6) | 6.4 (3.2) | 6.2 (3.0) | b:-1.17 (−2.04, −0.31) | 0.008 | b: −1.47 (− 2.33, − 0.60) | 0.001 | ||||
b Beta. OR Odds Ratio. Estimates are adjusted for patient age, sex, BMI and study months (number of months between study initiation and the patients’ baseline questionnaire). H/KOOS QoL = Hip disability and Osteoarthritis Outcome Score/ Knee injury and Osteoarthritis Outcome Score, Quality of Life subscale, (0–100. 100 = no problems)
Fig. 3Difference in OA related pain, function and disease activity between exercise program completers (exercised ≥2 times per week for ≥8 weeks) and non-completers
Association between exercise programme completers and selected baseline variables
| Variable | Completer | Non-Completer | Adjusted OR (95% CI) | |
|---|---|---|---|---|
| Age, mean (SD) | 63.4 (9.5) | 61.3 (9.8) | 1.02 (0.98, 1.05) | 0.2 |
| Sex, female, n (%) | 141 (77.0) | 62 (72.1) | 1.60 (0.86, 3.00) | 0.1 |
| BMI, mean (SD) | 28.5 (5.5) | 29.8 (5.9) | 0.97 (0.92, 1.02) | 0.2 |
| Education, ≥ 1 year university, n (%) | 65 (35.7) | 28 (32.9) | 1.07 (0.60, 1.91) | 0.8 |
| Living with someone, n (%) | 144 (78.7) | 66 (77.6) | 1.25 (0.63, 2.45) | 0.5 |
| Self-efficacy (10 worst-100 best), mean (SD) | 57.9 (17.6) | 55.5 (21.1) | 1.01 (0.99, 1.02) | 0.4 |
| Pain (NRS 0–10), mean (SD) | 5.2 (1.9) | 5.7 (2.1) | 0.94 (0.80, 1.09) | 0.4 |
The model includes random effects of cluster and individual participant and fixed effects for the other included variables and with additional adjustments for time (month of inclusion). OR = Odds ratio